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Abstract The aim of this study was to assess the response
to cytotoxic and hormone neo-adjuvant chemotherapy in
four patients with locally advanced breast cancer by
simultaneous PET/MRI. Four patients with locally
advanced breast cancer underwent simultaneous PET/MRI
of the breast using a 3 T Biograph mMR before and after
neo-adjuvant chemotherapy (two patients were treated with
hormone-therapy and two patients were treated with cyto-
toxic chemotherapy). Morpho-structural tumoral features
and tumor size were assessed; area value, metabolic (SUV
and MTV) and functional (ADC, Ktrans, Ve, kep and iAUC)
data were obtained by positioning regions of interest. A
comparison of all parameters between the pre- and post-
treatment PET/MRI examinations and between the two
different therapeutic schedules was assessed. In patients
treated with cytotoxic chemotherapy and classified as PR,
there was a significant reduction of post-treatment mor-
phological, metabolic and functional parameters. In a
patient treated with hormone therapy, classified as SD,
there was an increase of all post-treatment perfusion
parameters, a substantially stable ADC value and a poor
reduction of lesion size and of maximum SUV (SUVmax)
values; the last patient, treated with hormone therapy and
classified as PR, showed a significant reduction of lesion
size and SUVmax values with a reduction of perfusion
parameters and substantially stable ADC values. Multi-
parametric evaluation with simultaneous PET/MRI could
be a useful tool to assess the response to cytotoxic and
hormone neo-adjuvant chemotherapy in patients with
breast cancer. Future studies in a larger cohort of patients
are warranted to confirm the results of this preliminary
study.
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Introduction
Positron emission tomography/magnetic resonance imag-
ing (PET/MRI) is emerging as a powerful tool in the
assessment of response to treatment in oncologic patients,
with the possibility to simultaneously collect morphologic,
metabolic and functional parameters (diffusion and perfu-
sion parameters) [1]. Since its high contrast resolution in
breast tissue, the use of MRI in combination with PET is a
promising imaging technique for the evaluation of breast
tumor extension, nodal involvement, for the detection of
distant metastasis and for treatment monitoring [2, 3].
Moreover, preliminary studies suggest that simultaneous
18F-FDG and DCE MRI may aid in the assessment of
breast tumor aggressiveness and metastatic potential [4].
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In this short and preliminary report we specifically
evaluated the morphological, metabolic and functional
parameters in two groups of four patients with locally
advanced breast cancer before and after neo-adjuvant
chemotherapy (two patients were treated with hormone-
therapy, while the other two patients were treated with
cytotoxic chemotherapy), in order to assess the response to
treatment and to compare the behavior of such parameters
between the two groups.
Materials and methods
Patient population
Four patients underwent simultaneous PET/MRI of the
breast 2 h after 18F-FDG injection using a 3 T Biograph
mMR (Siemens Healthcare, Erlangen, Germany) with a
four-channel breast coil, before and after neo-adjuvant
chemotherapy. Of these, two patients were treated with
cytotoxic chemotherapy (Group 1), while the other two
patients were treated with hormone-therapy (Group 2).
Post-treatment evaluation was conducted at the end of the
second cycle of cytotoxic chemotherapy and after
2 months from the beginning of hormone therapy. Clinical
and histological post-surgical data for each patient are
reported in Table 1; in particular, there were two invasive
ductal carcinoma (IDC), one invasive lobular carcinoma
(ILC) and one invasive ductal/lobular carcinoma. The
study was approved by our Institutional Review Board and
informed consent was obtained from all individual partic-
ipants included in the study.
PET/MRI acquisition
A dose of 401 ± 35 MBq of [18F]-FDG was injected
depending on patient’s body weight. After an uptake period
80 ± 16 min, patients underwent PET/MRI examination.
PET/MRI was performed on the Biograph mMR (Sie-
mens Healthcare, Erlangen, Germany). This system con-
sists of a 3T MRI scanner featuring high-performance
gradient systems (45 mT/m) and a slew rate of 200 T/m/s.
The coils, patient table and cables have been redesigned for
PET/MRI in order to minimize their attenuation and, thus,
to allow unimpaired PET acquisition with the coils in
place. A fully functional PET system, equipped with the
avalanche photodiode technology, is embedded into the
magnetic resonance gantry. The PET scanner has a spatial
resolution of 4.1 mm (FWHM) at 1 cm and of 5.0 mm
(FWHM) at 10 cm from the transverse FOV and a sensi-
tivity of 11.72 kcps/MBq at the center of the FOV. Bed
position was established in order to get a full coverage of
the breast region. After a correct positioning had been
ensured, the combined PET/MRI acquisition started. First,
a coronal 2-point Dixon 3-dimensional volumetric inter-
polated breath-hold T1-weighted MRI sequence was
acquired and used for the generation of attenuation maps
and for anatomic allocation of the PET results. The soft-
ware of the MRI scanner automatically generated four
different images: T1-weighted in-phase, T1-weighted out-
of-phase, water-only and fat-only. Simultaneously with the
start of the Dixon MRI sequence, PET acquisition started
ensuring correct temporal and regional correspondence
between MRI and PET data. The PET data acquisition
occurred during the entire MR acquisition time, taking
delayed acquisition times and radioactive decay into
account.
MRI-based attenuation correction
For attenuation correction of the PET data from the PET/
MR scanner, attenuation maps generated on the basis of the
Dixon MRI sequence were applied. The attenuation maps
were generated on the basis of the 2-point Dixon MRI
sequences. This approach has recently been demonstrated
to provide results comparable to those of conventional
attenuation correction by low-dose CT [5]. The procedure
has been implemented in the post-processing software of
the scanner and operates automatically. The Dixon fat- and
water-weighted images were used to create an attenuation
map with four distinct tissue-classes: background, lungs,
fat and soft tissue. The lungs were identified by connected-
Table 1 Patient population
Patient Age Location Histological type Grade ER (%) PG (%) Ki67 (%) HER2 (%) NAC
1 54 Left IDLC G3 90 75 20 0 Cytotoxic
2 36 Right IDC G3 85 \1 20 3? Cytotoxic
3 42 Right IDC G2 90 90 5 0 Hormone
4 76 Left ILC G2 85 30 10 0 Hormone
IDLC invasive ductal/lobular carcinoma, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER estrogen receptor, PG progesterone
receptor, NAC neo-adjuvant chemotherapy
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component analysis of the air in the inner part of the body.
By application of a morphologic closing filter, virtual air
artifacts induced by the absence of an MRI signal in cor-
tical bone, heart and aorta (because of blood flow) were
corrected. Attenuation of the PET signal caused by
instrumentation such as the patient bed and the fixed MRI
coils is automatically integrated into the attenuation maps.
MR acquisition
The MRI protocol was performed with a dedicated breast
coil, including:
• Axial and coronal STIR (repetition time, echo time,
inversion time TR/TE/TI = 4220/61/220 ms);
• Axial diffusion-weighted imaging (DWI), a single-shot
echo planar 2d SPAIR (TR/TE = 9900/69 ms) using
three b values: 0, 500 and 800 s/mm2.
• Perfusion (DCE) studies were obtained with intra-
venous administration of paramagnetic contrast agent
(Magnevist, Bayer, Berlin, Germany) 0.2 ml/kg, a flow
rate of 3.5 ml/s, after two pre-contrast transaxial
T1Vibe with flip angles of 15 and 2 degrees followed
by a t1vibe_tra_dynamic (TR/TE = 5.37/1.78 ms) with
50 measurements. Additionally, an axial isovolumetric
VIBE FAT SAT axial and axial FFE FAT SAT T1 (TR/
TE = 8.7/4.3 ms) were acquired.
Data processing and multiparametric analysis
PET data obtained on PET/MR scanner were processed with
reconstruction and correction algorithms. Emission data
were corrected for randoms, dead time, scatter and attenua-
tion. A 3-dimensional attenuation-weighted ordered-subsets
expectation maximization iterative reconstruction algorithm
(AW OSEM 3D) was applied with three iterations and 21
subsets, Gaussian smoothing of 4 mm in full width at half
maximum and a zoom of 1.
Two radiologists experienced in breast imaging (16 and
8 years experience), and one nuclear medicine specialist
(16 years experience) evaluated PET/MRI images in con-
sensus. Response to treatment was assessed according to the
RECIST and PERCIST criteria [6, 7] and classified as com-
plete response (CR), partial response (PR), stable disease
(SD) or progression disease (PD). Lesion size was measured
considering the maximum lesion diameter (mm), while the
tumoral area (cm2) was quantified by positioning regions of
interest (ROIs) over the tumoral lesions in the major diameter
lesion slice; post-contrast T1-weighted and STIR-weighted
images were utilized to assist in the breast tumor outline.
In PET images, regional tracer uptake was quantified by
positioning ROIs over the tumoral lesions at the level of
maximum extension to obtain 2D maximal and mean
standardized uptake values (SUVmax 2D, SUVmean 2D); 3D
maximal and mean standardized uptake values (SUVmax
3D, SUVmean 3D, MTV) were obtained by positioning a
volume-of-interest (VOI) over the tumoral lesions with a
threshold of 30% of the maximum signal intensity (MTV
30).
Tumor detection, tumoral extension and infiltration of
neighboring structures were assessed mainly on MR
dynamic sequences. Subsequently, the DCE-MR images
were transferred for post-processing to a workstation
running commercially available software for tissue per-
fusion estimation (Tissue 4D, Siemens Medical Systems,
Germany). After motion correction and registration of the
pre- and post-contrast acquisitions, T1 mapping was
automatically performed and a freehand region-of-interest
Table 2 Pre- and post-treatment morphological, metabolic and perfusion parameters
Parameter Cytotoxic neo-adjuvant chemotherapy Hormone neo-adjuvant chemotherapy
Pt 1
Pre-treat
Pt 1
Post-treat
Pt 2
Pre-treat
Pt 2
Post-treat
Pt 3
Pre-treat
Pt 3
Post-treat
Pt 4
Pre-treat
Pt 4
Post-treat
Tumor size (mm) 82 40 37 28 45 38 74 36
Tumor area (cm2) 27.18 6.58 4.83 3.25 12.78 11.6 13.3 6.36
SUVmax 2D (KBq/ml) 34 8.76 12 2.67 12 10 15.5 3.17
SUVmax 3D 42.2 12.7 12.1 2.67 15.1 12 5.76 1.88
MTV (cm3) 92.12 9.58 26.45 21.5 26.45 15.98 24.68 19.56
ADCmean 0.70 1.19 0.66 2.09 1.03 0.9 1.01 0.99
Ktrans mean 123 77 598 51 133.8 181 50.14 35.44
Ve mean 242 339 233.76 138.33 317 372 186.85 459
Kep mean 92.7 23.32 119.5 28.77 43.49 49.33 30.48 12.53
iAUC mean 518 204 552.94 35.2 237.13 366 143.35 115.52
Pre-treat pre-treatment, Post-treat post-treatment, SUV standard uptake volume, MTV metabolic tumor volume, ADC apparent diffusion
coefficient, iAUC initial area under the concentration curve
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(ROI) was plotted around the tumor including the neigh-
boring structures. The pharmacokinetic modeling was
based on a two compartment pharmacokinetic model
proposed by Toft and Kermode [8] that allows the cal-
culation of the following parameters: the influx volume
transfer constant between vascular and extravascular/ex-
tracellular space (EES) (Ktrans), the efflux rate constant
between vascular and EES (kep), the fractional volume of
EES (Ve) and the initial area under the concentration curve
(iAUC), defined as a measure of the total amount of
contrast agent delivered to and retained within the tumor
during the stated time period. Arterial input function (AIF)
was related to gadolinium dose injected and was modeled
by a bi-exponential function using an intermediate mode
provided by the software. For the subsequent tumor ROI
analysis, PET/MRI datasets (PET acquisition, axial T1
post-contrast and axial STIR sequences, axial ADC map
and single perfusion maps for Ktrans, Ve, kep and iAUC)
were evaluated into a unified measurements framework
customized into Syngo.via software platform (Siemens
Medical Solutions) allowing a visual comparison of the
multiparametric data. AIF was calculated positioning a
ROI in the ascending aorta at the level of the right pul-
monary artery. Freehand ROI area value, referred as the
tumor size in the major diameter lesion slice, was
extracted for each patient. For multiparametric compar-
isons, the ROI outline was following drawn with same
position and extent on each map to automatically extract
maximum and mean values for each parameter (SUVmax
and SUVmean for the PET; ADCmax and ADCmean for the
Fig. 1 Multiparametric evaluation of morphological (STIR and T1
FS ? mdc), metabolic (PET) and functional (DWI, ADC, iAUC,
Ktrans, kep, Ve) parameters in a 54-year old female (Pt 1) with an
infiltrating ductal/lobular carcinoma of the left breast before cytotoxic
chemotherapy. A large tumoral mass with significant post-contrast
enhancement, increase of 18FDG uptake, restricted diffusivity and
increased perfusion is appreciated
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diffusion; Ktrans, Ve, kep, and iAUC, respectively, max and
mean for perfusion maps).
Since the small sample size, no statistical analysis was
performed and a direct comparison of the pre- and post-
treatment values for each patient and between the two
groups of patients treated with the two different thera-
peutic schedules was carried out.
Results
A total of four lesions were observed on pre- and post-
treatment PET/MR examinations. Mean size of lesions was
59 mm (range 37–82 mm). Three cases (patients 1, 2 and
4) were classified as PR according to both RECIST (lesion
size) and PERCIST (SUVmean values) criteria. In patient 3,
there was a less pronounced reduction of tumor size
(maximum diameter and tumor area) and 18-FDG uptake,
consistent with SD. In detail, in patients 1 and 2, treated
with cytotoxic chemotherapy and classified as PR, there
was a significant ([30%) post-treatment reduction of lesion
size, SUVmax values, perfusion parameters (except for Ve
mean) and a valuable increase of ADC values. In patient 3,
treated with hormone therapy and classified as SD, there
was an increase of all post-treatment perfusion parameters,
a substantially stable ADC value and a poor reduction of
lesion size and SUVmax values (\30%); patient 4, treated
with hormone therapy and classified as PR, showed a sig-
nificant reduction of lesion size ([30%) and SUVmax val-
ues with a reduction of perfusion parameters (except for Ve
mean) and substantially stable ADC values.
Fig. 2 Multiparametric evaluation of morphological (STIR and T1
FS ? mdc), metabolic (PET) and functional (DWI, ADC, iAUC,
Ktrans, kep, Ve) of the same patient reported in Fig. 1 (Pt 1) after the
second cycle of cytotoxic chemotherapy. A significant reduction of
tumor volume, FDG uptake, perfusion and an increased diffusivity are
now detected compared to the pre-treatment evaluation
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All the values of pre- and post-treatment morphological,
metabolic and perfusion parameters for each patient are
showed in Table 2.
Examples of pre- and post-treatment multiparametric
analysis are, respectively, illustrated in Figs. 1 and 2.
Discussion
A previous paper has shown the value of pre-treatment
DWI, DCE MRI parameters (Ktrans) and 18F-FDG PET/CT
measure SUVmean as significant predictors for short-term
response, assessed after two cycles of cytotoxic neo-adju-
vant chemotherapy in breast cancer [9].
Of note, imaging of tumor glucose metabolism with
18F-fluorodeoxyglucose (18F-FDG) has gained widespread
use to study the biological activity of tumor and overall
prognosis of oncological patients [10]. ADC diffusion
parameter provides microstructural information at the
cellular level revealing area of restricted diffusivity,
expression of high cell density; it has been demonstrated
that diffusion technique can detect microstructural chan-
ges (increase in ADC values) before tumor size reductions
are seen [11]. DCE parameters (iAUC, Ktrans, Kep and Ve)
provide information about tumoral microvasculature, such
as tissue perfusion, capillary permeability and integrity,
and they are considered as promising biomarkers to
monitor the effect of therapies that affect tumoral vas-
cularization [12].
In our study we have evaluated the clinical value of
simultaneously acquired PET/MRI morphological, meta-
bolic and functional parameters (i.e., SUVmax, SUVmean,
MTV, ADC, iAUC, Ktrans, Kep and Ve) in a group of
four patients for the assessment of response to neo-ad-
juvant cytotoxic chemotherapy and hormone therapy. In
particular, we observed a significant reduction of post-
treatment iAUC, Ktrans and Kep values and an increase of
post-treatment ADC values in the two patients who
underwent cytotoxic chemotherapy (Pts 1 and 2). A less
pronounced but always significant reduction of the same
parameters was observed in patient 4 (PR). Conversely,
we have not observed the same changes of both diffusion
and perfusion post-treatment values in patient 3, classi-
fied as SD; in particular, the substantially stable ADC
values and the paradoxal increase of all perfusion
parameters were probably related to the poor response to
treatment. The less pronounced reduction of ADC and
perfusion parameters in patient 4, compared to patients 1
and 2, could reflect the different mechanism of action of
the 2 therapeutic schedules. A possible hypothesis could
be the more direct cytotoxic effect of standard
chemotherapy compared to hormone therapy resulting in
cell death with following reduction in cell density and/or
release of pro-angiogenic cytokines. Conversely, hormone
therapy, determining an indirect effect on cell prolifera-
tion by the inhibition of estrogen receptors, could have a
less pronounced effect on cell density and especially on
neoangiogenesis.
In conclusion, our preliminary results suggest that
multiparametric evaluation with simultaneous PET/MRI
could be a useful tool to assess the response to cytotoxic
and hormone neo-adjuvant chemotherapy in patients with
breast cancer. Future studies in a larger cohort of patients
are warranted to confirm the results of this study and to
further evaluate the role of pharmacokinetic modeling in
simultaneous PET/MRI imaging.
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